BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 11148344)

  • 21. Planned neck dissection after concomitant radiochemotherapy for advanced head and neck cancer.
    Frank DK; Hu KS; Culliney BE; Persky MS; Nussbaum M; Schantz SP; Malamud SC; Holliday RA; Khorsandi AS; Sessions RB; Harrison LB
    Laryngoscope; 2005 Jun; 115(6):1015-20. PubMed ID: 15933512
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cisplatin, tegafur, and leucovorin: a moderately effective and minimally toxic outpatient neoadjuvant chemotherapy for locally advanced squamous cell carcinoma of the head and neck.
    Wang HM; Wang CS; Chen JS; Chen IH; Liao CT; Chang TC
    Cancer; 2002 Jun; 94(11):2989-95. PubMed ID: 12115388
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of hyperfractionation and conventional fractionation radiotherapy with concurrent docetaxel, cisplatin and 5-fluorouracil (TPF) chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).
    Katori H; Tsukuda M; Watai K
    Cancer Chemother Pharmacol; 2007 Aug; 60(3):399-406. PubMed ID: 17096160
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501).
    Bernier J; Cooper JS; Pajak TF; van Glabbeke M; Bourhis J; Forastiere A; Ozsahin EM; Jacobs JR; Jassem J; Ang KK; Lefèbvre JL
    Head Neck; 2005 Oct; 27(10):843-50. PubMed ID: 16161069
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas: II--clinical results.
    Lauve A; Morris M; Schmidt-Ullrich R; Wu Q; Mohan R; Abayomi O; Buck D; Holdford D; Dawson K; Dinardo L; Reiter E
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):374-87. PubMed ID: 15380569
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Concomitant low-dose cisplatin and three-dimensional conformal radiotherapy for locally advanced squamous cell carcinoma of the head and neck: Analysis of survival and toxicity.
    Lau H; Brar S; Hao D; MacKinnon J; Yee D; Gluck S
    Head Neck; 2006 Mar; 28(3):189-96. PubMed ID: 16265658
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chemotherapy in the management of advanced cutaneous squamous cell carcinoma in organ transplant recipients: theoretical and practical considerations.
    Martinez JC; Otley CC; Okuno SH; Foote RL; Kasperbauer JL
    Dermatol Surg; 2004 Apr; 30(4 Pt 2):679-86. PubMed ID: 15061855
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Attempts to improve organ preservation in patients with squamous cell carcinoma of the head and neck].
    Taguchi T; Tsukuda M
    Gan To Kagaku Ryoho; 2005 Dec; 32(13):2030-4. PubMed ID: 16352924
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management and palliative chemotherapy for metastatic or recurrent squamous cell carcinoma of the head and neck.
    Machiels JP; Schmitz S
    Expert Rev Anticancer Ther; 2011 Mar; 11(3):359-71. PubMed ID: 21534878
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Standard, and novel cytotoxic and molecular-targeted, therapies for HNSCC: an evidence-based review.
    Murdoch D
    Curr Opin Oncol; 2007 May; 19(3):216-21. PubMed ID: 17414639
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hypofractionated accelerated radiotherapy with concurrent chemotherapy for locally advanced squamous cell carcinoma of the head and neck.
    Sanghera P; McConkey C; Ho KF; Glaholm J; Hartley A
    Int J Radiat Oncol Biol Phys; 2007 Apr; 67(5):1342-51. PubMed ID: 17241752
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adjuvant radiotherapy after transoral laser microsurgery for advanced squamous carcinoma of the head and neck.
    Pradier O; Christiansen H; Schmidberger H; Martin A; Jäckel MC; Steiner W; Ambrosch P; Kahler E; Hess CF
    Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1368-77. PubMed ID: 16169679
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Induction chemotherapy with S-1 plus cisplatin in patients with locally advanced squamous cell carcinoma of the head and neck.
    Choi YJ; Chung JS; Shin HJ; Cho GJ; Wang SG; Lee BJ; Cho BM; Joo YD; Sohn CH
    J Laryngol Otol; 2008 Aug; 122(8):848-53. PubMed ID: 18047761
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reporting of time-to-event end points and tracking of failures in randomized trials of radiotherapy with or without any concomitant anticancer agent for locally advanced head and neck cancer.
    Le Tourneau C; Michiels S; Gan HK; Siu LL
    J Clin Oncol; 2009 Dec; 27(35):5965-71. PubMed ID: 19805677
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck.
    Colevas AD
    J Clin Oncol; 2006 Jun; 24(17):2644-52. PubMed ID: 16763278
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A comparison of treatment outcomes by radiochemotherapy and postoperative radiotherapy in locally advanced squamous cell carcinomas of head and neck.
    Fortin A; Caouette R; Wang CS; Vigneault E
    Am J Clin Oncol; 2008 Aug; 31(4):379-83. PubMed ID: 18845998
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Necessity for adjuvant neck dissection in setting of concurrent chemoradiation for advanced head-and-neck cancer.
    Brizel DM; Prosnitz RG; Hunter S; Fisher SR; Clough RL; Downey MA; Scher RL
    Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1418-23. PubMed ID: 15050318
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Factors associated with long-term dysphagia after definitive radiotherapy for locally advanced head-and-neck cancer.
    Caudell JJ; Schaner PE; Meredith RF; Locher JL; Nabell LM; Carroll WR; Magnuson JS; Spencer SA; Bonner JA
    Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):410-5. PubMed ID: 18635320
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Systemic chemotherapy with cisplatin plus 5-FU (PF) for recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): efficacy and safety of a lower dose of PF (80/800) at a single institution in Japan.
    Kiyota N; Tahara M; Kadowaki S; Fuse N; Doi T; Minami H; Ohtsu A
    Jpn J Clin Oncol; 2009 Apr; 39(4):225-30. PubMed ID: 19211574
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Emerging drugs for head and neck cancer.
    Rhee JC; Khuri FR; Shin DM
    Expert Opin Emerg Drugs; 2004 May; 9(1):91-104. PubMed ID: 15155138
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.